EZH2 and prostate carcinoma: Taken together, our data propose a new model of prostate cancer progression, where ADT and beta adrenergic signaling concordantly regulate PKA/CREB activation, EZH2 activity, TSP1 expression, angiogenesis, NED, and NEPC progression (Fig. 10g).